Tryp Therapeutics is a clinical-stage drug development company developing psilocybin products for various diseases/disorders including fibromyalgia.
Tryp Therapeutics
The company is very new and you can find their investor presentation here.
Tryp Therapeutics has raised a total of U$1.58 in funding over 1 round. This was a Post-IPO Equity round raised on Feb 5, 2021. They are registered under the ticker CNSX: TRYP.
Key Staff
- James Kuo – CEO
- William Garner – Executive Chairman
- Jay Campbell – CBO
- Robin Carhart-Harris – Scientific Advisor
News
- Tryp Therapeutics Reaches Milestone on Psilocybin Drug Manufacturing Program (press release, February 2021)
- Tryp Therapeutics Appoints Dr. Robin Carhart-Harris to Scientific Advisory Board (press release, February 2021)
- Tryp Therapeutics Partners with Albany Molecular Research Inc. to Manufacture a Proprietary Psilocybin-based Drug (press release, August 2020)
Activities
B2B
B2C
Drug Discovery
Topics of Interest
Fibromyalgia
Eating Disorders
Explore more company info with a Tree membership
📰 Weekly newsletter about the business of psychedelics
📈 Extended company information (analyst view, fundraising, revenue numbers)
🪄 Priority company page updates
Company News
Tryp Therapeutics Initiates Enrollment for Binge Eating Disorder Study in Partnership with University of Florida (Tryp Therapeutics, 23 March 2022)TRYP Therapeutics Doses First Patients in Phase 2 Psilocybin Trial (Microdose Psychedelic Insights, 28 April 2022)
Tryp Therapeutics Provides Update on Clinical Hold for Phase 2a Study for Eating Disorders (, 18 November 2021)
Tryp Therapeutics to Present at the H.C. Wainwright Psychedelics Conference on December 6, 2021 (, 03 December 2021)
Tryp Therapeutics Announces Advancement of Phase 2a Clinical Trial in Binge Eating Disorder (TRYPF) (, 23 December 2021)